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ABSTRACT
Objectives: Recent research strongly suggests that
genetic variation inﬂuences smokers’ ability to stop.
Therefore, the use of (pharmaco) genetic testing may
increase cessation rates. This study aims to assess the
intention of smokers concerning undergoing genetic
testing for smoking cessation and their knowledge,
attitudes and preferences about this subject.
Design: Online cross-sectional survey.
Setting: Database internet research company of which
every inhabitant of the Netherlands of $12 years with
an email address and capable of understanding Dutch
can become a member.
Participants: 587 of 711 Dutch smokers aged
$18 years, daily smokers for $5 years and smoke on
average $10 cigarettes/day (response rate¼83%).
Primary and secondary outcome
measures: Smokers’ knowledge, attitudes and
preferences and their intention to undergo genetic
testing for smoking cessation.
Results: Knowledge on the inﬂuence of genetic factors
in smoking addiction and cessation was found to be
low. Smokers underestimated their chances of having
a genetic predisposition and the inﬂuence of this on
smoking cessation. Participants perceived few
disadvantages, some advantages and showed
moderate self-efﬁcacy towards undergoing a genetic
test and dealing with the results. Smokers were mildly
interested in receiving information and participating in
genetic testing, especially when offered by their
general practitioner (GP).
Conclusions: For successful implementation of
genetic testing for smoking in general practice, several
issues should be addressed, such as the knowledge on
smoking cessation, genetics and genetic testing
(including advantages and disadvantages) and the
inﬂuence of genetics on smoking addiction and
cessation. Furthermore, smokers allocate their GPs
a crucial role in the provision of information and the
delivery of a genetic test for smoking; however, it is
unclear whether GPs will be able and willing to take on
this role.
INTRODUCTION
With currently still over 1.2 billion smokers
worldwide, tobacco smoking continues to be
To cite: Quaak M, Smerecnik
C, van Schooten FJ, et al.
Knowledge, attitudes and
preferences regarding
genetic testing for smoking
cessation. A cross-sectional
survey among Dutch
smokers. BMJ Open 2012;2:
e000321. doi:10.1136/
bmjopen-2011-000321
< Prepublication history and
additional materials for this
paper are available online. To
view these ﬁles please visit
the journal online (http://
bmjopen.bmj.com).
Received 18 August 2011
Accepted 7 November 2011
This ﬁnal article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
2.0 Licence; see
http://bmjopen.bmj.com
1Department of Toxicology,
Nutrition and Toxicology
Research Institute Maastricht
(NUTRIM), Maastricht
University, Maastricht, the
Netherlands
2Department of General
Practice, Care and Public
Health Research Institute
(CAPHRI), Maastricht
University, Maastricht, the
Netherlands
3Department of Health
Promotion, Care and Public
Health Research Institute
(CAPHRI), Maastricht
University, Maastricht, the
Netherlands
Correspondence to
Marieke Quaak; m.quaak@
maastrichtuniversity.nl
ARTICLE SUMMARY
Article focus
- Intention of smokers to undergo genetic testing
for smoking cessation.
- Smokers’ knowledge, attitudes and preferences
regarding genetic testing for smoking.
- To aid decisions on the most appropriate
strategies for counselling patients and commu-
nicating their test results with regard to a genetic
test for smoking.
Key messages
- Smokers are mildly interested in receiving more
information and participating in genetic testing
for smoking cessation, especially when offered
by their general practitioner.
- Knowledge on smoking cessation, genetics and
genetic testing (including advantages and disad-
vantages) and the inﬂuence of genetics on
smoking cessation is low.
Strengths and limitations of this study
- This study provides valuable information on the
needs and attitudes of smokers regarding genetic
testing for smoking cessation, which can aid
decisions for future implementation.
- Under-representation smokers intending to stop
smoking might have led to an underestimation of
smokers interested in genetic testing.
- Low knowledge level on genetic testing for
smoking cessation and genetics in general
might have inﬂuenced participants’ ability to
answer the questions.
- Interest in undergoing genetic testing may reﬂect
a generally positive attitude towards genetic
testing rather than actual uptake.
- Selection bias might have occurred due to the
non-representative nature of the internet popu-
lation and the self-selection of participants
(volunteer effect); however, unlikely due to high
response rate (83%).
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Open Access Researchthe largest preventable cause of disease and premature
death.
1e3 Cessation reverses most adverse effects of
smoking.
4 Although most smokers are highly motivated
to quit and many (pharmacological) treatments are
available to help them, cessation rates remain low; the
average 12-month success rate ranges from 15% to 30%,
5
but substantial variability exists in success rates across
smokers. Therefore, multiple quit attempts are often
required.
Recent research strongly suggests that smokers vary in
their underlying genetic susceptibility to become
addicted to smoking and their ability to stop smoking.
5e9
Genetic variation may also inﬂuence a smoker’s response
to a particular smoking cessation pharmacotherapy.
Hence, overall effectiveness of smoking cessation phar-
macotherapy may potentially be increased if it will be
targeted at smokers most likely to respond to a particular
type of pharmacotherapy. Reviews concerning prelimi-
nary ﬁndings of studies investigating the effect of genetic
polymorphisms on smoking cessation suggest promising
effects,
51 01 1making the use of (pharmaco) genetic
testing for smoking in clinical practice for increasing
quit rates by genetically tailored smoking cessation
treatment in the near future more likely.
Future implementation of (pharmaco) genetic testing
for smoking in daily medical practice, however, will
ultimately depend upon smokers’ acceptance of these
tests. At present, there is relatively little knowledge about
the willingness and preferences of smokers concerning
genetic testing for smoking addiction and cessation and
about individuals’ knowledge and attitudes on this
subject.
The goal of this study, therefore, is to investigate the
intention of smokers to undergo genetic testing for
smoking cessation and their knowledge, risk percep-
tions, attitudes and self-efﬁcacy beliefs. Additionally, we
assessed their preferences concerning a genetic test for
smoking cessation, such as topics and channels of
interest, and test characteristics. This information can be
used to guide the future development of a (pharmaco)
genetic test for smoking cessation.
METHODS
Study design
Smokers’ knowledge, attitudes and preferences and
their intention to undergo genetic testing were assessed
using an online cross-sectional survey.
Recruitment
Participants were selected from the database of an
internet research company originating from Maastricht
University (Flycatcher Internet Research B.V., Maas-
tricht, the Netherlands). The company has a database
of w20000 members from which representative samples
can be drawn. Every inhabitant of the Netherlands
of $12 years with an email address and capable of
understanding Dutch can become a member. Members
are recruited via digital media, written invitations,
face-to-face contacts and intermediaries. Since 2009, the
panel is certiﬁed with a quality mark (ISO-26326).
Participants were eligible for inclusion if they were
aged $18 years, were daily smokers for $5 years and
smoked on average $10 cigarettes/day. In total, 711
participants that met the inclusion criteria were
approached for this study. Two emails could not be
delivered. Of the remaining invitations, 614 people
responded. However, 26 questionnaires were not
completely ﬁlled out, and one case was removed because
the ﬁll out time indicated that this participant could not
have read the questions before answering. Thus, a total
of 587 participants were included in the present study
(response rate¼83%).
Questionnaire
The questionnaire was conducted in Dutch (questions in
manuscript translated by authors) and took about
30 min to complete. Respondents were compensated for
their time according to the standard of the research
company (eg, respondents receive a number of points
which can be exchanged for a gift certiﬁcate when
a certain amount is reached).
Participant characteristics
Participants’ age, gender and education level were
available from the company. In addition, participants
were asked questions regarding their smoking behaviour
(type of tobacco product, number of cigarettes and/or
shags per day, level of nicotine dependence (assessed by
the Fagerstro ¨m Test for Nicotine Dependence
12),
previous quit attempts (number, duration, period until
last attempt) and intention and intended period to quit.
Knowledge
Knowledge was assessed using 10 statements (see
table 1), two regarding smoking cessation in general,
four regarding the inﬂuence of genetics on nicotine
dependence and four regarding the inﬂuence of
genetics on smoking cessation (treatment). Participants
were asked whether they agreed or disagreed with the
statements or did not know the answer. In addition,
participants were asked how important environment,
personal behaviour and genetic predisposition were
according to them as a cause for smoking.
Risk perceptions
Participants were requested to estimate their probability
that they have a genetic predisposition as a result
of which they will have more difﬁculty to stop smoking
or they will experience more withdrawal symptoms
(1: very small to 5: very high), as well as to indicate the
seriousness of this (1: completely not serious to 5: very
serious).
Attitudes and self-efﬁcacy beliefs
Attitudes towards undergoing genetic testing were
assessed by 10 questions on the perceived advantages
and 10 questions on the disadvantages and self-efﬁcacy
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Genetic testing for smoking cessation(eg, ability to undergo a genetic test and to deal with the
results) using four questions (1: completely disagree to
5: completely agree; see table 2).
Topics and channels of interest
Participants were asked about which of the given topics
they would like to receive more information, via which
channels they would prefer to receive more information
regarding a genetic test to help them stop smoking and
via which channels they would prefer to actually obtain
the test.
Test characteristics
Participants were asked how important a number of test
characteristics (easily performable, reliability, fast result,
sharp increased cessation rates, low price, covered by
insurance) were for them when they would consider to
undergo a genetic test to help them stop smoking
(1: very unimportant to 5: very important). Furthermore,
participants were asked which maximum price they
would be willing to pay for the genetic test.
Intention to undergo genetic testing
Participants were asked if they were planning to undergo
a genetic test to determine which smoking cessation
therapy they could use best and if they were planning to
undergo a genetic test if it was offered by their general
practitioner (GP) or if they would ask their GP for
a genetic test (1: strongly disagree to 5: strongly agree).
RESULTS
Participant characteristics
Participant characteristics and characteristics of the
general Dutch smoking population can be found in
table 3. No signiﬁcant differences were found in terms of
gender, age group, education level, amount of cigarette
smokers and number of cigarettes smoked. Slightly more
participants had attempted to quit smoking and they had
undertaken slightly more quit attempts. A larger part of
the sample smoked shag (rolling tobacco), but fewer
smoked pipe/cigar/cigarillo’s. Furthermore, partici-
pants seemed less interested in quitting than the general
smoking population.
Knowledge
Table 1 presents the percentage of correct, incorrect and
‘don’t know’ answers.
The ﬁrst set of statements concerned respondents’
knowledge about smoking cessation. Overall, 88.9%
knew that it is important to quit. About half (49.1%) of
the respondents knew that less than half of the smokers
who want to quit succeed, while 29.8% could not answer
this question.
The second set measured whether respondents were
aware of how genetic factors inﬂuence smoking addic-
tion levels. About half of the participants could not
answer these questions (42.6%e59.6%). The lowest
percentage of correct scores was found for the state-
ments regarding the transfer of a genetic predisposition
Table 1 Knowledge of smoking cessation and inﬂuence of genetic factors on smoking addiction and smoking cessation
(treatment)
Correct (%) Incorrect (%) Don’t know (%)
Smoking cessation
It is important to quit smoking, even if you already smoke for a very
long time (T)
88.9 4.3 6.8
More than half of the smokers who want to quit smoking succeed
in quitting (F)
49.1 21.1 29.8
Inﬂuence of genetic factors on smoking addiction levels
The chance to become addicted to smoking is inﬂuenced by the
presence of certain hereditary traits (genes) (T)
29.5 27.9 42.6
Genes exist that increase the chance to become addicted to
smoking (T)
33.4 15.5 51.1
Genes exist that decrease the chance to become addicted to
smoking (T)
15.5 24.9 59.6
A parent with a genetic predisposition to get addicted to smoking
will transfer this predisposition to its children, even when the parent
doesn’t smoke or has never smoked (T)
14.0 33.2 52.8
Inﬂuence of genetic factors on smoking cessation (treatment)
A genetic predisposition to get addicted to smoking might also inﬂuence
ones chance to quit smoking (T)
25.4 21.1 53.5
Due to a genetic predisposition can a smoking cessation therapy
(eg, nicotine patches) be less effective for certain smokers (T)
26.4 17.6 56.0
Due to a genetic predisposition can a smoking cessation therapy
(eg, nicotine patches) be more effective for certain smokers (T)
15.2 24.5 60.3
A genetic predisposition can inﬂuence the chance on withdrawal
symptoms during a cessation attempt (T)
23.9 18.7 57.4
T, this statement is true; F, this statement is false.
Quaak M, Smerecnik C, van Schooten FJ, et al. BMJ Open 2012;2:e000321. doi:10.1136/bmjopen-2011-000321 3
Genetic testing for smoking cessationto the offspring by a non-smoking parent and the exis-
tence of genes that decrease the chance of becoming
addicted to smoking (14.0% and 15.5%, respectively).
About one-third knew that the chance to become
addicted to smoking is inﬂuenced by genes (29.5%) and
that genes exist that increase the chance of becoming
addicted to smoking (33.4%).
The third set assessed knowledge of the inﬂuence of
genetic factors on smoking cessation and smoking
cessation treatment. More than half of the respondents
could not answer these (53.5%e60.3%). About a quarter
knew that a genetic predisposition might also inﬂuence
ones chances to quit (25.4%), can make cessation
therapy less effective for certain smokers (26.4%) and
inﬂuences the chance on withdrawal symptoms during
cessation (23.9%). Only 15.2% knew that a genetic
predisposition can also make a cessation therapy more
effective for certain smokers.
Table 2 Attitudes and self-efﬁcacy beliefs
Completely
disagree (%)
Disagree
(%)
Neutral
(%)
Agree
(%)
Completely
agree (%)
Disadvantages
If I would undergo a genetic test.
.the results will become known at my work/to
my employer.
39.9 29.3 26.1 3.9 0.9
.the results will become known to my health
insurance.
23.7 20.6 33.2 18.9 3.6
.and it will show that I am addicted to smoking
will it be more difﬁcult to get a mortgage or
life-insurance.
19.4 22.1 32.7 19.9 5.8
.the results may be passed on to all kinds
of agencies.
21.8 26.6 34.6 12.9 4.1
.I will learn about other diseases I have a
predisposition for.
11.8 15.5 43.3 26.1 3.4
.I will be worried for the results. 9.0 24.7 40.4 23.2 2.7
.I will be afraid of the results. 10.9 27.4 42.2 16.5 2.9
.I will regret it due to possible consequences. 10.4 27.9 44.5 14.8 2.4
.I will worry about the possible results of the
genetic test.
9.7 22.7 40.0 23.9 3.7
.I will not be able to tell the results to others. 15.0 38.2 38.8 6.6 1.4
Advantages
If I would undergo a genetic test.
.this will indicate the correct smoking cessation
therapy for me.
4.6 13.5 55.5 21.5 4.9
.this will increase the chances that I succeed
to stop smoking.
6.1 13.8 54.9 20.6 4.6
.this will help to determine the correct dose of
smoking cessation medication.
5.1 10.6 51.4 27.8 5.1
.I will have less side-effects from smoking
cessation treatments.
6.0 16.5 61.0 13.5 3.1
.this can prevent that I take/undergo an incorrect
smoking cessation treatment.
5.5 11.1 56.4 22.0 5.1
.I will feel better since I know I have done
everything I can to understand my smoking
addiction.
12.6 21.6 50.3 14.1 1.4
.I will feel relieved by the results. 7.8 15.8 43.1 29.5 3.7
.I will be proud of myself. 9.0 21.3 52.5 14.8 2.4
.I will be happy that I know my genetic risk. 9.5 19.9 45.5 21.3 3.7
.I will feel reassured. 12.6 21.6 50.3 14.1 1.4
Self-efﬁcacy
Do you believe you will be able to.
.undergo a genetic test? 7.5 18.2 38.0 20.3 16.0
.ask you GP for a genetic test when you have a
need for it?
7.2 20.4 39.7 20.1 12.6
.understand the results of the genetic test? 3.2 8.0 48.9 27.3 12.6
.undergo the correct treatment based on the
results of the genetic test?
4.6 10.6 49.2 17.5 18.1
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Genetic testing for smoking cessationFurthermore, most respondents believed that envi-
ronment and personal behaviour were (very) important
causes for smoking (80% and 84%, respectively), while
only 36% believed that genetic predisposition is an
(very) important cause of smoking (supplementary
ﬁgure S1).
Risk perceptions
About one-third of the participants believed their prob-
ability to be (very) small to have a genetic predisposition
as a result of which they will have more difﬁculty to stop
smoking (38.3%) or have more withdrawal symptoms
(39.4%) (supplementary table S1). On the other hand,
about one-ﬁfth (16.8% and 15.3%, respectively) believed
their probability to be (very) big.
About half of the participants believed this to be (very)
serious (53.9% and 51.5%), about two-ﬁfth (35.6% and
39.2%) to be neutral and about one-tenth (9.4% and
10.6%) to be (completely) not serious (supplementary
table S1).
Attitudes and self-efﬁcacy beliefs
Attitudes regarding genetic testing (perceived advan-
tages and disadvantages) and self-efﬁcacy beliefs can be
found in table 2.
About one-third to half of the participants did not
agree with the statements about the disadvantages of
genetic testing and about one-third to two-ﬁfth had
a neutral reaction, while only less then one-third
(completely) agreed with these statements. Especially,
the chance that the results would become known at work
or to the employer and that they would not be able to tell
others was perceived as low (4.8% and 8.0%
(completely) agreed, respectively).
On the other hand, only about one-third or less
(completely) disagreed with the statements on the
advantages of genetic testing (12.8%e34.2%), while
about half (43.1%e61.0%) had a neutral reaction and
12.8%e33.2% (completely) agreed. Participants were
least convinced that they would be relieved by the results
and most convinced that a genetic test would give
Table 3 Baseline characteristics of the research sample (compared with the general smoking population)
Sample (n[587) Dutch smoking
population* n/mean %/SD Range
Demographics
Gender (n, %)
Male 292 49.7 53.6%
Female 295 50.3 46.4%
Age (n, %)
20e39 years 192 32.7 41.0%
40e64 years 336 57.2 50.7%
>65 years 59 10.1 8.3%
Level of education (n, %)
Low 184 31.3 39.0%
Medium 267 45.5 36.6%
High 136 23.2 24.4%
Smoking characteristics
Type of tobacco product smoked (n, %)
Cigarettes 430 73.3 67.0%
Shag (rolling tobacco) 360 61.3 48.0%
Pipe/cigars/cigarillo’s 28 4.8 17.0%
Other 5 0.8 e
Number of cigarettes/shags smoked per day
(mean, SD)
19.0 7.5 10e50 14.4
FTND score (mean, SD) 4.6 2.1 0e10 e
FTND score >6 (n, %) 215 36.6 e
Cessation characteristics
Previously attempted to quit (n, %) 437 74.4 65.0%
Number of previous attempts to quit (mean, SD) 2.9 3.1 1e40 2.2
Duration longest quit attempt, days (mean, SD) 269.7 623.1 0e4015 e
Period until last quit attempt, years (mean, SD) 3.9 5.1 0e30 e
Intention to quit smoking (n, %) 305 52.0 78.0%
Intended period until quit attempt, years (n, %)
Within 1 month 22 3.7 11.0%
Within 3 months 53 9.0 13.0%
Within 6 months 50 8.5
Within 1 year 109 18.6 14.0%
More than 1 year from now 71 12.1 40.0%
*TNS Nipo/STIVORO. Continu Onderzoek rookgewoonten (COR) (continuous research smoking habits), 2009.
FTND, Fagerstro ¨m Test for Nicotine Dependence.
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position to become addicted to smoking, and that it
could help to determine the correct dose of smoking
cessation medication.
About a quarter of the participants were unsure if they
would be able to ask their GP for a genetic test or
undergo a genetic test (27.6% and 25.7%, respectively),
while about two-ﬁfth (39.7% and 38.0%) had a neutral
reaction and one-third (32.7% and 36.3%) (totally)
agreed with these statements. Furthermore, they agreed
even somewhat more to the beliefs that they would be
able to undergo the correct treatment based on the
results of the test and to understand the results of the
genetic test. Only, about 10%e15% (totally) disagreed
with these statements, about half (48.9% and 49.2%,
respectively) did not agree or disagree with them and
about two-ﬁfth (39.9% and 35.6%) (totally) agreed with
them.
Topics and channels of interest
About one-third of the participants (29.3%) were not
interested in more information (see supplementary
ﬁgure S2A). However, 28.4% were interested in more
information on how DNA works, 35.8% in what a genetic
predisposition is and 50.9% in the working mechanism
of a genetic test. Furthermore, 42.9% were interested in
where more information can be found about the genetic
background of smoking and 43.1% in more information
about the inﬂuence of genetic differences on (smoking
cessation) treatments.
Most participants (73.6%) would prefer to receive
more information from their GP (supplementary ﬁgure
S2B). Other channels via which participants would
prefer to receive more information are the internet
(48.0%), specialists (37.6%), leaﬂets (22.5%), TV
(12.4%), newspapers (7.7%), friends (6.0%), a tele-
phonic help-desk (5.3%), magazines (4.9%), radio
(2.4%) and books (2.2%).
Most participants (67.6%) would also prefer to obtain
the genetic test via their GP (supplementary ﬁgure S2C).
Other preferred channels for obtaining the test were
expert/specialist (33.4%), the pharmacy (18.1%),
internet (15.5%) and the pharmacist (9.2%), while
15.5% was not interested in obtaining a genetic test.
Test characteristics
The most important test characteristic according to the
participants of this study is reliability (supplementary
ﬁgure S3); 82% of the participants believed this to be
(very) important. Other test characteristics were also
indicated as (very) important by most participants;
covered by insurance (78%), a low price (74%), a sharp
increase in cessation rates (71%) and a fast result (65%).
Most participants (64.7%) indicated not to be willing
to pay >V50 for the genetic test. About a quarter of
the participants (24.2%) are willing to pay V50eV150,
8.9% willing to pay V150eV200 and only 2.2% is willing
to pay >V200.
Intention to undergo genetic testing
Only a low number of participants (16.6%) were
(completely) interested in undergoing a genetic test to
determine which smoking cessation therapy they could
use best (see supplementary table S2). From the
remaining participants, slightly less than half were
(completely) not interested in undergoing a genetic test
(43.5%) and about the same proportion was undecided
as to whether or not they would be willing to undergo
a genetic test (40.0%).
The intention to undergo genetic testing increased
considerably when it would be offered by their
GP (38.3%). On the other hand, only 7.8% would ask
their GP for the genetic test, while about half of the
participants (50.6%) would not ask their GP for the test.
DISCUSSION
Signiﬁcant advances have been made in elucidating the
role of genetic factors in nicotine dependence and
response to smoking cessation treatment. Although
much work still remains to be done, the use of genetic
testing for increasing quit rates by genetically tailored
smoking cessation treatment in clinical practice is on the
horizon. However, at present, few studies have investi-
gated the needs and attitudes of smokers on this subject.
Therefore, in this study, we investigated knowledge,
attitudes and preferences of smokers on genetics of
smoking and their willingness to undergo genetic testing
for smoking addiction and treatment.
This study provides valuable information, which can
aid decisions on the most appropriate strategies for
counselling patients and communicating their test
results.
The results showed that misconceptions regarding
smoking cessation rates using current smoking cessation
(pharmaco) therapies need attention. Even though most
smokers knew it is important to quit smoking, only about
half of them knew that less than half of the smokers who
want to quit smoking will succeed. In practice cessation,
rates are even much lower; only 15%e30% will succeed
in long-term quitting using the available treatments,
5
and these rates are even lower when no treatment is
used. Since smokers overestimate their chances to be
able to quit smoking using the current (pharmaco)
therapies, they might underestimate the positive effects
of a genetic test for smoking. However, we should be
careful with presenting this information to smokers since
this might also demotivate smokers to start a quit
attempt.
The knowledge level on the inﬂuence of genetic
factors on smoking addiction and cessation, and possibly
also basic mechanisms of heredity, is highly inadequate
and should be addressed as well. These results are
comparable with a previous study,
13 which also found
that smokers, ex-smokers and non-smokers had little
knowledge about genetic contributions to smoking and
smoking-related behaviours. Furthermore, the most
popular topics for receiving more information were the
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Genetic testing for smoking cessationworking mechanism of a genetic test, where more
information about the genetic background of smoking
can be found, and the inﬂuence of genetic differences
on (smoking cessation) treatments. This conﬁrms the
lack of knowledge about the inﬂuence of genetics on
smoking and smoking cessation that was found in this
study. Moreover, about one-third of the participants were
also interested in more information on what a genetic
predisposition is and how DNA works, indicating
a further lack of knowledge on genetics in general.
Besides, smokers seem to considerably underestimate
their chances of having a genetic predisposition and the
inﬂuence of this on smoking and smoking cessation,
which could lead to an underestimation of the impor-
tance of undergoing a genetic test for smoking as well.
Respondents were found to perceive the probability of
having a genetic predisposition to be (very) small to
average, even though many of the genetic variants that
have been shown to inﬂuence smoking behaviour are
prevalent in the population.
6 14 Comparable results were
found by another study,
13 in which 53% perceived
themselves as “not at all likely” or “somewhat likely” to
have inherited a genetic predisposition to smoking,
while 47% perceived themselves to be ‘moderately’ to
‘extremely likely’. Furthermore, we found that most
participants did not belief that a genetic predisposition
is an (very) important cause of smoking, while it has
been shown that genetic factors account for a vast part of
the variance in smoking initiation, maintenance and
cessation success.
57 e9 In the previously mentioned
study, also only a small part of the participants believed
that inheriting a gene that predisposes them to smoke is
the most important factor that causes people to smoke,
although smokers were signiﬁcantly more likely to agree
with this.
13 Recently, we have shown in a theoretical
modelling study based on the results of this survey that
smokers who perceive a higher susceptibility or severity
have a higher intention to undergo genetic testing.
15
Thus, increasing awareness of the probability and
consequences of having a genetic predisposition might
also be an effective strategy to motivate smokers to
undergo a genetic test for smoking cessation.
Moreover, participants were found to perceive little
disadvantages of genetic testing for smoking addiction
and cessation but some advantages. Only a small part of
the participants in this study were concerned that the
results would become known at their work or to their
employer, their health insurance or other agencies and
that it would become more difﬁcult to get a mortgage or
life insurance when a genetic test would show that they
were addicted to smoking. On the contrary, research in
other areas has shown that those in the USA are partic-
ularly concerned about the potential for genetic test
results to become available to their employer, health
insurance or life insurance.
16 17 These differences might
be explained by the difference in laws in place to protect
against the misuse of genetic information by employers
and insurers. In some countries, genetic testing is
explicitly regulated with regard to all aspects (eg,
Austria, the Netherlands and Norway); in others; the
regulation has focused only on the insurance industry
(eg, Denmark and Sweden) or even only on group
health insurers (eg, USA).
18 Therefore, to motivate
smokers to undergo a genetic test, they could be made
more aware of the advantages of genetic testing as well.
However, disadvantages should not be under-repre-
sented either because smokers may then inaccurately
perceive the beneﬁts and risks associated with genetic
testing. Since fear has been shown to decrease intention
to undergo genetic testing in our theoretical modelling
study,
15 increasing awareness of advantages and disad-
vantages could decrease fear for genetic testing and
might thereby result in an increased uptake of a genetic
test for smoking cessation.
Uptake might be further increased when smoker’s
ability to undergo a genetic test and deal with the results
(eg, self-efﬁcacy) is improved. Currently, only 30%e40%
of the participants believed to be able to cope with
a genetic test for smoking cessation. In our theoretical
modelling study, intention to undergo genetic testing
was found to increase when smokers feel they would be
able to cope with the results.
15
Finally, it seems that smokers allocate their GPs
a crucial role in the provision of information on this
subject and the delivery of a genetic test for smoking.
Thus, it seems likely that GPs will play an important role
in the counselling of patients about undergoing genetic
testing. However, several studies indicate that they may
not have the knowledge, willingness or training to take
on this role.
19e22 Many GPs were not sure if they would
be able to understand the meaning of genetic test
results, how such information should direct clinical care
and their ability to effectively communicate genetic
information to patients.
21 Furthermore, physicians are
concerned that integrating genetic testing into their
practice would also add to their already restricted time
constraints.
21
Thus, for successful implementation of genetic testing
for smoking in general practice, several issues should be
addressed, such as the knowledge on smoking cessation,
genetics and genetic testing (including advantages and
disadvantages) and the inﬂuence of genetics on smoking
addiction and cessation. Of course, patients are not
expected to be experts in this ﬁeld. However, patients
will need to have a certain level of insight on this subject.
Without this knowledge, smokers will not be able to
understand the test and the results properly. Therefore,
they will not be able to make an accurate decision
whether or not to undergo a genetic test for smoking
nor to undergo the right treatment based on the results.
GPs are likely to play an important role in the informa-
tion provision since they will have to help their patients
to make the decision to undergo a genetic test and
provide them with the treatment based on this test.
However, due to the time constraints, it will probably not
possible for a GP to fully explain this test to their patients
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be interested in such a test if they do not have some
knowledge about the inﬂuence of genetic factors on
smoking and smoking cessation. Therefore, these issues
should also be addressed via other channels of commu-
nication, for instance, information leaﬂets or informa-
tion campaigns on TV, radio or in magazines or
newspapers.
This study is subject to several limitations. First, the
ﬁeld of pharmacogenetic inﬂuences on smoking cessa-
tion is still in its infancy, and therefore, no well-accepted
tests to tailor smoking cessation treatment are commonly
available. However, it is of crucial importance to inves-
tigate the expectations of the smokers that are willing to
quit before a genetic test can be developed that will
enter the market. This knowledge on smokers’ expecta-
tions can drive the implementation, promotional
strategy and the information given when the test will
become available. Therefore, from a health promotion
and marketing perspective, it is appropriate to start
asking these questions at this time.
Second, as smokers may not be familiar with
genetic testing for smoking addiction and genetically
tailored cessation treatments or even genetics in
general, it is questionable whether they were able to give
a well-considered answer to all our questions.
Third, as Sanderson and colleagues
23 argued, interest
in undergoing genetic testing may reﬂect a generally
positive attitude towards genetic testing rather than
actual uptake. Thus, to determine actual uptake of
genetic testing, further studies are needed where
respondents are offered the possibility to undergo
genetic testing.
Fourth, our sample under-represented smokers
intending to stop smoking, which could have led to an
underestimation of the willingness to undergo genetic
testing.
Fifth, since participants were recruited via an internet
research company, selection bias might have occurred
due to the non-representative nature of the internet
population and the self-selection of participants (volun-
teer effect). The effect of bias due to the non-represen-
tative nature of the internet population will probably be
minimal since no difference in internet use is expected
among smokers. The potential for self-selection bias can
be estimated by measuring the response rate; the fairly
high response rate (83%) decreases the chance
for selection bias. Furthermore, several studies have
shown that the validity and reliability of data obtained
online are comparable to those obtained by classical
methods.
24e28
Finally, since this survey was conducted among Dutch
smokers only, the results might not be completely
generalisable to other smoking populations. Genetic
testing is explicitly regulated in the Netherlands
18;
therefore, it is to be expected that smokers perceive less
disadvantages of genetic testing than smokers in other
countries were regulation is less explicit. Smokers are
thus likely to perceive more disadvantages of genetic
testing in countries with less regulation, as has been
found in the USA,
16 17 which might decrease their
intention to undergo genetic testing for smoking cessa-
tion. Furthermore, the level of education is likely to
inﬂuence the knowledge level. However, since the
education level in the Netherlands is relatively high and
even here the knowledge level is low, it is not to be
expected that the knowledge level is adequate in other
countries. Indeed, comparable results have been found
before.
13 Moreover, in the Netherlands, the GP plays
a central role in the provision of healthcare and that is
probably why Dutch smokers allocate their GPs an
important role in the provision of information and the
genetic test itself. This could be different for countries
with another healthcare system. However, it is to be
expected that intention will be increased when it is
offered by the primary healthcare provider in other
countries as well, regardless of the type of primary
healthcare provider. However, the general conclusions
will probably also apply to other countries. And the results
from this study also provide a good starting point for the
investigation of this issue among other populations.
In general, we may conclude that Dutch smokers are
interested in genetic testing for smoking cessation,
especially when offered by their GP. However, before
successful implementation of genetic testing for
smoking in general practice will be possible, several
issues should be addressed, such as the knowledge on
smoking cessation, genetics and genetic testing
(including advantages and disadvantages) and the
inﬂuence of genetics on smoking addiction and cessa-
tion. Furthermore, GPs attitudes and knowledge should
be addressed as well.
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